Treatment of mice with the anticoccidial drug Toltrazuril does not interfere with the development of a specific cellular intestinal immune response to Eimeria falciformis.
Immunity against Eimeria-infections is highly specific and it depends on cell-mediated effector mechanisms. Infections of BALB/c mice with 1,000 sporulated oocysts of Eimeria falciformis led to protection against challenge infections. Treatment with the anti-coccidium Toltrazuril, during primary infection, terminated the ongoing disease and did not interfere with the establishment of protective immunity against challenge infections. Mesenteric lymph node cells of infected, treated as well as non-treated and challenged BALB/c mice, showed a similar proliferation upon stimulation with parasite antigen. In contrast, neither cells of the Peyer's patches, intraepithelial lymphocytes, nor spleen cells responded to stimulation with parasite antigens. Cells from all compartments and of all investigated groups proliferated and released the cytokines IFN-gamma and IL-4 in response to the mitogen Concanavalin A. The number of cells releasing IFN-gamma or IL-4 was not dependent on the status of infection or previous treatment with Toltrazuril. The serum IgG response against total sporozoite antigens of individual mice showed that in addition, a systemic humoral response developed in infected mice, independent of a previous drug treatment, although the specific IgG antibody concentration was higher in non-treated mice. Thus, Toltrazuril does not impair the parasite specific intestinal cellular and systemic antibody response and does not prevent the development of protection against challenge infection.
Steinfelder
Svenja
S
Department of Molecular Parasitology, Humboldt University, Philippstrasse 13, 10115 Berlin, Germany.
Lucius
Richard
R
Greif
Gisela
G
Pogonka
Thomas
T
D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D000953:Antigens, Protozoan / Q000276:immunology; D002478:Cells, Cultured; D003048:Coccidiosis / Q000188:drug therapy* / Q000276:immunology*; D003049:Coccidiostats / Q000627:therapeutic use*; D003208:Concanavalin A / Q000494:pharmacology; D004539:Eimeria / Q000276:immunology*; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D007371:Interferon-gamma / Q000096:biosynthesis; D015847:Interleukin-4 / Q000096:biosynthesis; D007422:Intestines / Q000276:immunology*; D008198:Lymph Nodes / Q000276:immunology; D008213:Lymphocyte Activation; D008221:Lymphoid Tissue / Q000276:immunology*; D008643:Mesentery / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D013045:Species Specificity; D014227:Triazines / Q000627:therapeutic use*
D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D003049:Coccidiostats; D007074:Immunoglobulin G; D014227:Triazines; D003208:Concanavalin A; D015847:Interleukin-4; D007371:Interferon-gamma; C036670:toltrazuril